Search

Displaying results 1671 - 1680 of 10000 in total
  1. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.

  2. Drug

    Rivoceranib

    go.drugbank.com/drugs/DB14765
    Investigational

    Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

  3. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence. … [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

  4. Drug

    Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14385
    ApprovedInvestigationalWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze
  5. Drug

    Sodium phosphate, dibasic, unspecified form

    go.drugbank.com/drugs/DB14504
    Approved

    Mixtures: Aminosyn II in Dextrose, Aminosyn II with Electrolytes
  6. Drug

    Ethinylestradiol

    go.drugbank.com/drugs/DB00977
    ApprovedInvestigational

    Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability. … [A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.

    Mixtures: Lenea 20 µg/75 µg überzogene Tabletten, PIL KB I KOMBINASI
  7. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen

    go.drugbank.com/drugs/DB10285
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … Neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused

    Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
  8. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen. … SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB.

    Synonyms: N-adamantanyl-N'-geranyl-ethylenediamine
  9. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Synonyms: L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
  10. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the